Because we wouldn't. We'd just license it to someone like Acadia anyway. Unless we had reason to believe it would be on substantially better terms than what we're getting now then it makes little difference. Furthermore, if NNZ-2591 turns out to be substantially better than trof and shows great promise in an indication like any of those I would expect Acadia to approach Neuren to fund trials using NNZ-2591 instead of spending the same amount of money to fund trials using trof with a lower chance of success.
Because we wouldn't. We'd just license it to someone like Acadia...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.07 |
Change
-0.400(2.76%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $14.47 | $14.53 | $13.99 | $7.843M | 552.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2150 | $14.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.10 | 1129 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |